Chondroitin Sulfate CS b-Bioactive Delays the Progression of Knee Osteoarthritis, Study Finds

beadbb9b-265e-4f43-972f-34f9381b5b8carticleimage.jpg

28 Jun 2017 --- Bioiberica’s Chondroitin sulfate CS b-Bioactive delays osteoarthritis progression and is as effective as the anti-inflammatory drug celecoxib at improving the disease’s symptoms. These are the main conclusions of a clinical essay presented by Professor Jean Pierre Pelletier at the Annual European Congress of Rheumatology, held in Madrid. Conducted by Bioiberica, the MOSAIC clinical essay (a 24-month study on structural changes in knee osteoarthritis assessed by MRI with Chondroitin sulfate) is a multicenter, randomized, double-blind, controlled and comparative study, carried out in five medical centers in Quebec (Canada). 

A total of 194 patients suffering from knee osteoarthritis with inflammation (synovitis) and moderate pain participated in the study to assess the effects of chondroitin sulfate (1.200 mg/day) and celecoxib (200 mg day) over the loss of cartilage volume in knee osteoarthritis after 24 months. 

The participants underwent three Quantitative Magnetic Resonance scans: one at the beginning of the study, the second one after one year and a third one at the end of the study. The results revealed that the progression of knee osteoarthritis is slower in patients who received chondroitin sulfate CS b-Bioactive. This group experienced a statistically significant lower loss of cartilage volume as soon as after the first year of treatment, in comparison with those patients who received the anti-inflammatory drug.

Patients treated with chondroitin sulfate had a decrease in synovitis which was associated with a statistically significant decrease in cartilage loss. In addition to that, a post hoc analysis of this clinical trial concludes that chondroitin sulfate also has a protective effect by reducing the long-term progression of knee OA structural changes caused by a decrease in the loss of subchondral bone curvature. 

“This data proves that chondroitin sulfate may delay the advance of osteoarthritis in the long term, and identifies a possible new mode of action of chondroitin sulfate,” Professor Pelletier said. 

The MOSAIC study also evaluated the effects of both products on the disease’s symptoms. Among others, the study evaluated their effects on pain, function, stiffness, joint swelling and effusion; concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50 percent.

“The study confirms that both products are effective for the treatment of osteoarthritis symptoms, although only chondroitin sulfate has the additional advantage of exerting a joint protection effect,” Professor Pelletier concludes.

Related Articles

Business News

Nutrition 21 launches US media campaign to support Velositol ingredient

11 Dec 2017 --- Nutrition 21, LLC has partnered with NYC-based media relations firm Pitch Publicity and clinical pharmacist James B. LaValle in a national media tour dedicated to educating consumers about the benefits of its proprietary ingredient, Velositol.

Nutrition & Health News

Soy, cruciferous vegetables linked to fewer breast cancer treatment side effects

11 Dec 2017 --- Consuming soy foods and cruciferous vegetables – such as cabbages, kale, collard greens, bok choy, Brussels sprouts and broccoli – may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, according to a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center. Understanding the role of life style factors with regard to the side effects is important because diet can serve as a modifiable target for possibly reducing symptoms among breast cancer survivors.

Business News

Inflammatory bowel disease rates on the rise outside West, says new study

08 Dec 2017 --- Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialized and Westernized, a new study has found. The research – a collaboration between the University of Birmingham, UK, the University of Calgary, Canada, and the Chinese University of Hong Kong – is described by the University of Birmingham as the most definitive and comprehensive study of the global epidemiology of inflammatory bowel disease.

Business News

Consuming sugary drinks during pregnancy may increase asthma risk in mid-childhood

08 Dec 2017 --- Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research published online in the Annals of the American Thoracic Society.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

More Articles
URL : http://www.nutritioninsight.com:80/news/chondroitin-sulfate-cs-b-bioactive-delays-the-progression-of-knee-osteoarthritis-study-finds.html